MyMD Pharmaceuticals Announces Dr. Mitchell Glass As President And CMO
$MYMD
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
MyMD Pharmaceuticals Announces Dr. Mitchell Glass As President And CMO
Save time and jump to the most important pieces.
SC 13D - MyMD Pharmaceuticals, Inc. (0001321834) (Subject)
SC 13G - MyMD Pharmaceuticals, Inc. (0001321834) (Subject)
SC 13G/A - MyMD Pharmaceuticals, Inc. (0001321834) (Subject)
New name and stock symbol represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system
New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic systemCompany plans mid-stage clinical trials of TNF-alpha inhibitor drug MYMD-1® following statistically significant Phase 2 studiesTNF Pharmaceuticals will begin trading on Nasdaq under the new trading symbol "TNFA" effective July 24, 2024TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) (the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced a rebranding to the new name "TNF Pharmaceuticals, Inc.," effective today. The Company's common stock,
As Benzinga Cannabis Capital Conference returns to Chicago this Oct. 8-9 for its 19th edition, gathering top CEOs, investors and investors and leaders in the cannabis industry, let’s scroll through the latest leadership changes in the space. Get your tickets now before prices surge by following this link. Kicking off with Margaret Brodie, CEO of Rubicon Organics Inc. (TSXV:ROMJ) (OTCQX:ROMJF), who has recently been nominated as an EY Entrepreneur Of The Year 2024 finalist in Pacific. The company shared the news in an X post earlier in June. Canadian cannabis giant Canopy Growth Corporation (TSX:WEED) (NASDAQ:CGC) recently appointed Ryan Keith, a senior commercial leader with over two d
New name and stock symbol represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) (formerly MyMD Pharmaceuticals, Inc.) (the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced that its common stock, listed on the Nasdaq Capital Market, begins trading under the new ticker symbol, "TNFA," effective before the market open today, July 24, 2024. The new trading symbol "TNFA" replaces the Company's previous trading symbol "MYMD" and coincides with the Company's previously announced corporat
New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system Company plans mid-stage clinical trials of TNF-alpha inhibitor drug MYMD-1® following statistically significant Phase 2 studies TNF Pharmaceuticals will begin trading on Nasdaq under the new trading symbol "TNFA" effective July 24, 2024 TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) (the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced a rebranding to the new name "TNF Pharmaceuticals, Inc.," effective today. The Company's com
Dr. Glass brings a 35-year career in life sciences with multiple drug approvals including Accolate ®, Avandia ® and Coreg® Dr. Glass brings broad expertise in regulatory strategies: 5 NDAs and MAAs, 7 pre-NDA meetings, 12 End of Phase 2 meetings, and more than 80 INDs Company announces President and CMO transition as clinical development advances through mid-stage trials Company also appoints new independent board member, Mr. Stephen Friscia, an experienced investment strategist MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflamm
Dr. Glass brings a 35-year career in life sciences with multiple drug approvals including Accolate ®, Avandia ® and Coreg® Dr. Glass brings broad expertise in regulatory strategies: 5 NDAs and MAAs, 7 pre-NDA meetings, 12 End of Phase 2 meetings, and more than 80 INDs Company announces President and CMO transition as clinical development advances through mid-stage trials Company also appoints new independent board member, Mr. Stephen Friscia, an experienced investment strategist MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflamm
MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, announced today that it has appointed David Rini to the Company's Scientific Advisory Board. "I am delighted to join the MyMD Scientific Advisory Board and look forward to working on the development and communication about our two platforms," stated David Rini. David Rini is a Professor at the Johns Hopkins University School of Medicine in the Department of Art of Applied to Medicine, Cellular and Molecular Medicine, and Director of the Medical and Biological Illustration Graduate Program. Professor Rini earned his M
MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced statistically significant positive topline Phase 2 results for its next generation Oral TNF-α inhibitor MYMD-1 in Sarcopenia/Age-Related Frailty earlier this week. In conjunction with its release, the company also announced it will hold a conference call today, August 2nd, at 4:30pm ET to discuss the results. To participate in the conference call, please register here. A webcast can also be accessed under the ‘Events & Presentations' section on the Investors page at w
- MYMD-1 significantly reduced serum levels of chronic inflammatory markers and met all primary pharmacokinetic and secondary safety and tolerability endpoints across multiple doses over 28 days of treatment - MYMD-1 demonstrated statistical significance across three biomarkers: TNF-α (P=0.008), sTNFR1 (P=0.02), and IL-6 (P=0.03) - First Oral TNF-α inhibitor, if approved, would offer potential patient benefit in large markets - Company to present the data to FDA and intends to advance the clinical program for MYMD-1; will hold conference call on August 2, 2023, at 4:30 PM Eastern Time MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage pharmaceutica
3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)
3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)
3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)
DEF 14A - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)
8-K - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)
S-3 - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)